A Study of OPC-262 in Patients With Type 2 Diabetes

NCT00997282 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

255

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Type 2

Interventions

DRUG: OPC-262 2.5 mg
DRUG: OPC-262 5 mg
DRUG: Placebo

Sponsor

Kyowa Kirin Co., Ltd.